Miami, FL (PRWEB) November 05, 2014

Global Stem Cells Group, its subsidiary Stem Cell Training, Inc. and Dr. J. Victor Garcia have announced plans to conduct the Adipose Derived Harvesting, Isolation and Re-integration Training Course in Barcelona, Spain Nov. 22-23. 2014.

The two-day, hands-on intensive training course, which will be conducted by Garcia, was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctors office by teaching effective, in-office regenerative medicine techniques.

For more information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

More here:
Global Stem Cells Group to Hold Practical, Hands-on Training Course on Adipose-derived Stem Cell Harvesting, Isolation ...

Freeport, Grand Bahama (PRWEB) November 05, 2014

Okyanos is the first to receive regulatory approval from the National Stem Cell Ethics Committee (NSEC) to provide adult stem cell therapy in its new state-of-the-art facility and has now begun treating patients. The licensing includes approval for cardiac cell therapy, as well as cell therapy for tissue ischemia, autoimmune diseases, and other chronic neurological and orthopedic conditions. The licensing criteria requires that approved protocols be supported by peer-reviewed papers showing substantial evidence of safety and efficacy.

"As the leader in cell therapy, Okyanos is very proud to bring a new standard of care and a better quality of life to patients who are looking for new options for unmet healthcare needs. said Matt Feshbach, CEO and co-founder of Okyanos. Adipose (fat)- derived stem and regenerative cells (ADRCs) are known to restore blood flow, modulate the immune system, reduce inflammation and prevent further cell death after a wound, helping the body begin the process of healing itself.

Adult stem cell therapy has emerged as a new treatment alternative for those who want to live a more normal life but are restricted in these activities due to their medical conditions. Just 50 miles from the US shore, Okyanos cell therapy is available to patients with severe heart disease including coronary artery disease (CAD) and congestive heart failure (CHF) as well as patients with auto-immune diseases, orthopedic, neurological and urological conditions. Okyanos cell therapy is performed in their new state-of-the-art facility built to exceed U.S. surgical center standards.

With the regulatory and licensing approvals for adult stem cell therapy, Okyanos is the first to treat patients with cell therapy for severe heart disease and other unmet medical conditions based on a combination of internationally approved cell processing technology, technical papers, clinical trials and in-clinic use which provide the basis for a new standard of care.

Patients can contact Okyanos at http://www.okyanos.com or by calling toll free at 1-855-659-2667.

About Okyanos: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos brings a new standard of care and a better quality of life to patients with coronary artery disease, tissue ischemia, autoimmune diseases, and other chronic neurological and orthopedic conditions. Okyanos Cell Therapy utilizes a unique blend of stem and regenerative cells derived from patients own adipose (fat) tissue which helps improve blood flow, moderate destructive immune response and prevent further cell death. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. The literary name Okyanos, the Greek god of the river Okyanos, symbolizes restoration of blood flow.

View post:
Okyanos Treats First Patients with Cell Therapy

16 hours ago

Researchers at the University of Cambridge have managed to reconstruct the early stage of mammalian development using embryonic stem cells, showing that a critical mass of cells not too few, but not too many is needed for the cells to being self-organising into the correct structure for an embryo to form.

All organisms develop from embryos: a cell divides generating many cells. In the early stages of this process, all cells look alike and tend to aggregate into a featureless structure, more often than not a ball. Then, the cells begin to 'specialise' into different types of cell and space out asymmetrically, forming an axis which begins to provide a structure for the embryo to develop along.

In animal embryos this stage is followed by a process known as gastrulation: a choreographed movement of the cells that, using the initial axis as a reference, positions the head and the tail, the front and the back. During the process, the cells begin to forum three distinct layers: the endoderm, mesoderm and ectoderm, determining which tissues or organs the cells will then develop into.

Professor Alfonso Martinez-Arias from the Department of Genetics at the University of Cambridge, who led the research, says: "Gastrulation was described by biologist Professor Lewis Wolpert as being 'truly the most important event in your life' because it creates the blueprint of an organism. Axis formation and gastrulation are the two central processes that initiate the development of an organism and are inextricably associated with the embryo. We have managed to recreate this for the first time in the lab."

This video is not supported by your browser at this time.

Professor Martinez-Arias and colleagues, supported by the European Research Council and the Wellcome Trust, have reconstructed these early stages of development using mouse embryonic stem cells. Embryonic stem cells, discovered in the Department of Genetics in the 1980s (for which Sir Martin Evans was awarded the Nobel Prize in Physiology or Medicine 2007), have become an important tool for developmental biology, understanding disease, and in regenerative medicine due to the ability to give rise to all cell types in culture. Over the last few years, they have been used to 'grow' organs including the eye and the cerebral cortex; surprisingly, these structures develop without an axis.

In research published today in the journal Development, the researchers report a way to coax cells to reorganize in the manner that they do in an embryo, creating an axis and undergoing movements and organisations that mimic the process of gastrulation. Over the years researchers have been making aggregates of embryonic stem cells to obtain certain cell types, for example red blood cells. However, these aggregates lack structure and the different cell types emerge in a disorganised fashion. This is the first time that researchers have been able to elicit axis formation, spatial organisation and gastrulation-like movements from aggregates of embryonic stem cells.

The researchers show that if the number of cells aggregated initially is similar to that of a mouse embryo, the cells generate a single axis and this serves as a template for a sequence of events that mimics those of the early embryo. By manipulating the signals that the cells see at a particular time, the researchers were able to influence what type of cell they become and how they are organised. In one of the experiments, for example, activation of a particular signal at the correct time elicits the appearance of the mesoderm, endoderm and ectoderm the precursors of all cell types with a spatial organization similar to that of an embryo.

Using this experimental system, the researchers were able to generate the early stages of a spinal cord, which they showed forms as part of the process of gastrulation. This finding complements previous research from the University of Edinburgh and the National Institute for Medical Research which showed that embryonic stem cells can be coaxed into this spinal cord cells; however, the Cambridge researchers showed that the in the embryo-like aggregates, the structural organization is more robust and allows for the polarised growth of the tissue.

Read the rest here:
Researchers reconstruct early stages of embryo development

PUBLIC RELEASE DATE:

4-Nov-2014

Contact: Craig Brierley craig.brierley@admin.cam.ac.uk 44-012-237-66205 University of Cambridge @Cambridge_Uni

Researchers at the University of Cambridge have managed to reconstruct the early stage of mammalian development using embryonic stem cells, showing that a critical mass of cells not too few, but not too many is needed for the cells to being self-organising into the correct structure for an embryo to form.

All organisms develop from embryos: a cell divides generating many cells. In the early stages of this process, all cells look alike and tend to aggregate into a featureless structure, more often than not a ball. Then, the cells begin to 'specialise' into different types of cell and space out asymmetrically, forming an axis which begins to provide a structure for the embryo to develop along.

In animal embryos this stage is followed by a process known as gastrulation: a choreographed movement of the cells that, using the initial axis as a reference, positions the head and the tail, the front and the back. During the process, the cells begin to forum three distinct layers: the endoderm, mesoderm and ectoderm, determining which tissues or organs the cells will then develop into.

Professor Alfonso Martinez-Arias from the Department of Genetics at the University of Cambridge, who led the research, says: "Gastrulation was described by biologist Professor Lewis Wolpert as being 'truly the most important event in your life' because it creates the blueprint of an organism. Axis formation and gastrulation are the two central processes that initiate the development of an organism and are inextricably associated with the embryo. We have managed to recreate this for the first time in the lab."

Professor Martinez-Arias and colleagues, supported by the European Research Council and the Wellcome Trust, have reconstructed these early stages of development using mouse embryonic stem cells. Embryonic stem cells, discovered in the Department of Genetics in the 1980s (for which Sir Martin Evans was awarded the Nobel Prize in Physiology or Medicine 2007), have become an important tool for developmental biology, understanding disease, and in regenerative medicine due to the ability to give rise to all cell types in culture. Over the last few years, they have been used to 'grow' organs including the eye and the cerebral cortex; surprisingly, these structures develop without an axis.

In research published today in the journal Development, the researchers report a way to coax cells to reorganize in the manner that they do in an embryo, creating an axis and undergoing movements and organisations that mimic the process of gastrulation. Over the years researchers have been making aggregates of embryonic stem cells to obtain certain cell types, for example red blood cells. However, these aggregates lack structure and the different cell types emerge in a disorganised fashion. This is the first time that researchers have been able to elicit axis formation, spatial organisation and gastrulation-like movements from aggregates of embryonic stem cells.

The researchers show that if the number of cells aggregated initially is similar to that of a mouse embryo, the cells generate a single axis and this serves as a template for a sequence of events that mimics those of the early embryo. By manipulating the signals that the cells see at a particular time, the researchers were able to influence what type of cell they become and how they are organised. In one of the experiments, for example, activation of a particular signal at the correct time elicits the appearance of the mesoderm, endoderm and ectoderm the precursors of all cell types with a spatial organization similar to that of an embryo.

Original post:
Shaping up: Researchers reconstruct early stages of embryo development

Mark and Mindy Ammons lost their 2-year-old son, Christopher, in 1988 to neuroblastoma, an aggressive childhood cancer. In 2009, Mindy Ammons donated her own stem cells to a woman with cancer. And this weekend, the family's youngest son will prepare a bone marrow donor registry in memory of his oldest brother as an Eagle Scout project.

Family photo

Bone marrow donation is close to the heart for the Ammons family of Provo.

Mark and Mindy Ammons lost their 2-year-old son, Christopher, in 1988 to neuroblastoma, an aggressive childhood cancer. In 2009, Mindy Ammons donated her own stem cells to a woman with cancer. And this weekend, the familys youngest son will lead a bone marrow registry drive as an Eagle Scout project in memory of his oldest brother.

We are in the unique position of having been on both sides of the process, Mindy Ammons said.

In the "Be The Match" flier created for the project, Will Ammons, 13, explains that Christophers only chance of survival was a bone marrow transplant, but sadly, no one in our family was a match, so he had to be his own donor.

Christopher underwent treatment at the UCLA Medical Center where, after five days of chemotherapy, three days of full-body radiation and then surgery, he received his own marrow as a transplant. He died two weeks into the process, just shy of his third birthday.

Over the years, the Ammonses talked about this experience with their children and stayed informed on treatment advances. When it came time for their second oldest son, Jon, to do his Eagle Scout project, he didn't just want to do something to check off on a list. He wanted a meaningful project.

He wanted to do something that would make a difference and was cancer-related," Mindy Ammons said.

They discussed raising money for cancer research but decided that would be like dropping a coin in a well, she said.

See the rest here:
Family honors child's memory through bone marrow registry and stem cell donation

Mark and Mindy Ammons lost their 2-year-old son, Christopher, in 1988 to neuroblastoma, an aggressive childhood cancer. In 2009, Mindy Ammons donated her own stem cells to a woman with cancer. And this weekend, the family's youngest son will prepare a bone marrow donor registry in memory of his oldest brother as an Eagle Scout project.

Family photo

Bone marrow donation is close to the heart for the Ammons family of Provo.

Mark and Mindy Ammons lost their 2-year-old son, Christopher, in 1988 to neuroblastoma, an aggressive childhood cancer. In 2009, Mindy Ammons donated her own stem cells to a woman with cancer. And this weekend, the familys youngest son will lead a bone marrow registry drive as an Eagle Scout project in memory of his oldest brother.

We are in the unique position of having been on both sides of the process, Mindy Ammons said.

In the "Be The Match" flier created for the project, Will Ammons, 13, explains that Christophers only chance of survival was a bone marrow transplant, but sadly, no one in our family was a match, so he had to be his own donor.

Christopher underwent treatment at the UCLA Medical Center where, after five days of chemotherapy, three days of full-body radiation and then surgery, he received his own marrow as a transplant. He died two weeks into the process, just shy of his third birthday.

Over the years, the Ammonses talked about this experience with their children and stayed informed on treatment advances. When it came time for their second oldest son, Jon, to do his Eagle Scout project, he didn't just want to do something to check off on a list. He wanted a meaningful project.

He wanted to do something that would make a difference and was cancer-related," Mindy Ammons said.

They discussed raising money for cancer research but decided that would be like dropping a coin in a well, she said.

Read the original:
Family saves lives through bone marrow registry and stem cell donation

OpRegen consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency that were derived from human embryonic stem cells (hESCs). Cell Cure will conduct the trial in Israel where OpRegen will be transplanted as a single dose into the subretinal space of the eye to test the safety and efficacy of the product. Patient enrollment is expected to begin in 2014 following approval of the trial by the Israel Ministry of Health.

About the OpRegenClinical Trial

Cell Cures Phase I/IIa clinical trial is a dose escalation safety and preliminary efficacy study of hESC-derived Retinal Pigment Epithelial (RPE) cells transplanted subretinally in patients with advanced dry-form AMD called geographic atrophy. The open-label, single center, nonrandomized trial will evaluate three different dose regimens of 50,000 to 500,000 cells. A total of 15 patients will be enrolled. The patients will be 55 years of age and older, with non-neovascular (dry-AMD) who have funduscopic findings of GA in the macula with absence of additional concomitant ocular disorders. The eye most affected by the disease will be treated with the contralateral eye being the control. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of OpRegen. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and induce changes in visual acuity. In addition to thorough characterization of visual function, a battery of defined ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. The study will be performed at Hadassah Ein Kerem Medical Center in Jerusalem, Israel.

The FDAs acceptance of our IND for the Phase I/IIa trial of OpRegen is a significant milestone for our company, and in the broader development of therapies based on human embryonic stem cells for the treatment of major diseases, said Benjamin Reubinoff, MD, PhD, Chief Scientific Officer of Cell Cure and Chairman of Obstetrics and Gynecology and Director of the Hadassah Human Embryonic Stem Cell Research Center at Hadassah Medical Center, Jerusalem, Israel. We look forward to initiating this first-of-its-kind study, and to continuing the clinical development of OpRegen.

Cell Cures Phase I/IIa study of OpRegen has been designed to provide preliminary, objective functional and structural data on the ability of hESC-RPE cell transplantation to slow the progression of geographic atrophy, in addition to safety data, added Prof. Eyal Banin, Head of the Center for Retinal and Macular Degenerations at the Department of Ophthalmology of Hadassah University Medical Center, Jerusalem, Israel who together with Prof. Reubinoff helped develop this novel treatment over the last decade. We are truly excited that this unique, hESC-based therapy will finally be tested in patients with dry-AMD which severely impacts the quality of life of the elderly, and for which no approved therapy yet exists, Dr. Banin stated.

Information about the trial will be made available at ClinicalTrials.gov website of the National Institutes of Health http://www.clinicaltrials.gov/ct2/home. Additional information will be made available on Cell Cures website at http://www.cellcureneurosciences.com/.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading eye disease responsible for visual impairment of older persons in the US, Europe and Australia. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly but may progress to geographic atrophy (GA) in which RPE cells and photoreceptors degenerate and are lost. Once the atrophy involves the fovea (the center of the macula), patients lose their central vision and may develop legal blindness. There are about 1.6 million new cases of dry-AMD in the US annually, and as yet there is no effective treatment for this condition. The yearly economic loss to the gross domestic product in the United States from dry-AMD has been estimated to be $24.4 billion. The market opportunity for a treatment for GA has been estimated at over $5 billion globally. About 10% of patients with dry-AMD develop wet (or neovascular) AMD, the second main form of this disease, which usually manifests acutely and can lead to severe visual loss in a matter of weeks. Wet-AMD can be treated with currently marketed VEGF inhibitors. However, such products typically require frequent repeated injections in the eye, and patients often continue to suffer from continued progression of the underlying dry-AMD disease process. Current annual sales of VEGF inhibitors for the treatment of the wet form of AMD are estimated to be about $7 billion worldwide.

The root cause of the larger problem of dry-AMD is believed to be the dysfunction of RPE cells. Therefore, one of the most exciting new therapeutic strategies for dry-AMD is the transplantation of healthy young RPE cells to support and replace those lost with age. Pluripotent stem cells, such as hESCs, can potentially provide a means of manufacturing such healthy RPE cells on an industrial scale.

About OpRegen

More:
BioTimes Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic ...

MIAMI (PRWEB) November 04, 2014

Global Stem Cells Group, Inc. has been named exclusive distributor for Adistem medical solutions, and Adilyfe, a new regenerative medicine products company founded by Adistem Ltd. Scientific Founder Vasilis Paspaliaris, M.D. in Melbourne, Australia and set to launch in early 2015. Paspaliaris made the announcement at the First International Symposium on Stem Cells and Regenerative Medicine held in Buenos Aires, Argentina Oct. 2-4 and hosted by Global Stem Cells Group.

Adistem-Adilyfe will manufacture a group of products for use in stem cell treatments, therapies and training through the Adimarket Division of the Global Stem Cells Group. The timing is perfect for GSCGs current expansion into Latin American countries including Colombia, Costa Rica, Chile, Mexico and Peru, according to Global Stem Cells Group CEO Benito Novas.

Vasilis, an accomplished biotech scientist, stem cell researcher and pharmaceutical consultant joined the Global Stem Cells Group Scientific Advisory Board, part of the Regenestem Network.

As always, Dr. Paspaliaris brings excellence to stem cell research, Novas says. His work has already proven critical to improving the quality of life for a range of chronically ill patients all over the world.

We are honored to be representing Adistem and AdiLyfe products in Latin America; we consider the opportunity a strategic commitment to world class stem cell research.

Vasilis says he knew Global Stem Cells Group would be the only choice to represent Adistem and AdiLyfe in Latin America.

We are proud of our relationship with Global Stem Cells Group, we couldnt ask for better partners, Vasilis says.

To learn more about the Global Stem Cells Group, visit the website at http://www.stemcellsgroup.com, email bnovas(at)stemcellsgroup(dot)com, or call 305.224.1858.

About Global Stem Cell Group:

View original post here:
Global Stem Cells Group Named Exclusive Distributor for Adistem and Adilyfe Companies and Product Lines

Heart Disease

With respect to the heart, stem cells have the ability to not only home into the damaged areas but also to initiate a cascade of biological events which both culminate in healing of the heart muscle. For example, animal studies have demonstrated that stem cell therapy will cause new muscle cells to be formed through stimulation of dormant stem cells that are already inside the heart muscle. In these studies, the administered stem cell also transformed into new heart muscle cells.

At Stem Cell Institute, our stem cell treatment protocol for heart failure involves administration of mesenchymal stem cells harvested from human umbilical cord tissue.

The adult stem cells used to treat heart failure at the Stem Cell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Medistem Panamas state-of-the-art laboratory.

The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births. Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.

All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.

Approximately 1 in 10 donated umbilical cords pass our rigorous screening process.

Through retrospective analysis of our cases, weve identified proteins and genes that allow us to screen several hundred umbilical cord donations to find the ones that we know are most effective. We only use these cells and we call them golden cells.

We go through a very high throughput screening process to find cells that we know have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration.

Read more here:
Stem Cell Therapy || Heart Failure || Stem Cell Treatment ...

Blue Horizon's Special Skin Serum Stem Product Fact Sheet

Our Stem Cell Skin Care is a potent anti-aging innovation derived from non-embryonic human stem cell research. Blue Horizon International has infused medicines most promising clinical advances into this powerful skin care product.

Cytokine action, epidermal growth factors (EGFs), short and long-chained hyaluronic acid and ceramides combat the effects of aging and deliver unique skin benefits without surgery.

Our formulation is safe, having passed toxicology tests in accordance with European Union regulation 1223/2009/EC.

Patents are pending.

Our skin care is derived from what stem cell scientists call a conditioned medium. Here, human stem cells from placentas and umbilical cords condition the culture medium by releasing cytokines and other skin regenerating proteins that become available for skin repair. We stabilize the liberated cytokines, rendering them safe and accessible for aesthetic skin improvement. The conditioned medium is the base for our stem cell skin care products.

An independent skin test on twenty individuals aged 46 to 81 found a 23% reduction in skin roughness, including a decrease in the appearance of fine lines, wrinkles and scars.

Cytokines are one of todays most exciting captured biological processes, because they govern so many regenerative functions. The cytokine group of chemical regulators includes a diverse assortment of interleukins, interferons and growth factors that control anti-aging and activate the bodys immune system.

Cytokines stimulate, propagate and regulate new cell production in human skin. These messaging molecules mobilize cell division to help heal age related damage. Cytokines have powerful influence over skin texture and quality because they regulate cell shape, metabolism and migration from one location to another.

Several stem cell skin care ranges claim cytokine-style benefits. However, human stem cell cytokines are more biologically compatible with human skin than cytokine proteins from other sources.

Continued here:
Stem Cell Skin Care - BlueHorizonSkinCare.com

Pioneers of transplantation John Gurdon
Interview with Sir John Gurdon, developmental biologist and forefather of stem cell medicine. The footage, produced by Figment Productions, formed part of an exhibition organised by the MRC...

By: Medical Research Council

Follow this link:
Pioneers of transplantation John Gurdon - Video

Study Identifies Potential Treatment Target for Cocaine Addiction

30 Oct 2014A study led by investigators from Massachusetts General Hospital and the Perelman School of Medicine at the University of Pennsylvania has identified a potential target for therapies to treat cocaine addiction. Read more

27 Oct 2014A new effort mapping 24-hr patterns of expression for thousands of genes in 12 different mouse organs five years in the making provides important clues about how the role of timing may influence the way drugs work in the body. Read more

27 Oct 2014An all-female panel of luminaries in fields including epigenetics and stem cell biology will come together at a Penn symposium entitled Celebrating Women in Science. The Department of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania, has organized the... Read more

22 Oct 2014A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis. Read more

22 Oct 2014Some of the most promising startup teams in healthtech will pitch their companies to an audience of several hundred investors, industry leaders and potential customers at DreamIt Health Philadelphia Demo Day on Thursday, October 30 from 9 a.m. to 2 p.m. at World Cafe Live in Philadelphia. Read more

See the original post here:
Perelman School of Medicine at the University of Pennsylvania

PURTIER LIVE STEM CELL THERAPY
PURTIER INTRODUCTION IN CHINESE Please contact Pearly @ +65 9338 9541 / +65 9189 7351 for more details.

By: Purtier30

Go here to read the rest:
PURTIER LIVE STEM CELL THERAPY - Video

JANUARY 2014 State of the Industry Briefing at EBD's Biotech Showcase Jan 13. San Francisco, CA EBD's Biotech Showcase: Regenerative Medicine Industry Track Jan 13-15. San Francisco, CA ECI's Conference on Scale-Up and Manufacturing of Cell-Based Therapies Jan 6-9. San Diego, CA International Conference on Cell Therapy for Cardiovascular Disease Jan 22-24. New York, NY Phacilitate's Cell and Gene Therapy Forum Jan 27-29. Washington, DC FEBRUARY 2014 RRY's New York Stem Cell Summit Feb 18. New York, NY STEMSO's International Stem Cell Society Conference Feb 19-22. Freeport, Grand Bahama BMT Tandem Meetings Feb 26-Mar.Grapevine (Dallas), TX MARCH 2014 Danish Stem Cell Symposium Mar 7-8. Hillerd, Denmark ISBioTech Spring Mtg - Cellular Therapies Track Mar 10-12. Washington, DC AAT's Advanced Therapies Summit Mar 12-13. Turin, Italy ISSCR/SBE International Conference on Stem Cell Engineering Mar 16-19. Coronado, CA Congress on Stem Cell and Cell Therapies Mar 2023. Koceli, Turkey FDA and the Changing Paradigm for HCT/P Regulation Mar 24-26. Bethesda, MD BIRAXs' UK-Israel Regenerative Medicine Conference Mar 25-26. Haifa, Israel ARM's RegenMed Investor Day Mar 26. New York, NY. Regenerative Medicine Workshop at Hilton Head Mar 26-29 . Hilton Head, SC Cancer Immunotherapy: A Long-Awaited Reality Mar 27. NYC, NY. FDA Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Public Mar 31. Silver Spring, MD.

APRIL 2014 Select Biosciences' Clinical Translation of Stem Cells Apr 21-22. Palm Springs, AZ ISCT Annual Meeting Apr 23-26. Paris, France GTCBio's Stem Cell Summit Apr 23-25. Boston, MA ARMs Annual Dinner & Legislative Fly-In Apr 28-9. Washington, DC.

MAY 2014 GeneExpression Systems' Stem Cells and Cell Signaling Mtg on Assays to Regenerative Medicine, Tissue Engineering and Therapeutics May 5-6. Waltham-Boston, MA Regenerative Medicine Foundation Symposium May 5-7. San Francisco, CA CHIsAdoptive T Cell Therapy:New Targets and Strategies for Immune Driven Diseases (part of the Tenth Annual PEGS: the essential protein engineering summit) May 7-8. Boston, MA ASGCT - American Society of Gene and Cell Therapy Mtg May 21-24. Washington, DC Terrapinn's World Stem Cells and Regenerative Medicine Congress May 20-22. London, UK JUNE 2014 PDA Europe: Advanced Therapy Medicinal Products Jun 3-4. Madrid, Spain The Orthobiologic Institute's PRP and Regenerative Medicine Symposium Jun 6-7. Los Angeles, CA Israstem Jun 10-11. Ramat, Gan. Israel TERMIS EU Mtg Jun 10-14. Genova, Italy ISSCR - International Society for Stem Cell Research Mtg Jun 18-21. Vancouver, BC, Canada Cell Tracking Symposium June 20. London, ON

BIO International Convention(with BPI BioProcess Theater) Jun 23-26. San Diego, CA ARM Networking Reception @BIO June 24. San Diego, CA OMIC'sCell Science and Stem Cell Research Jun 24-26. Valencia, Spain JULY 2014 The Business of Regenerative Medicine: New Therapies, New Models July 14-16. Toronto, ON Regenerative Medicine Essentials: The Fundamentals to the Future. July 21-25.Winston-Salem, NC

AUGUST 2014 CHI'sCell Therapy Bioproduction (part of the Bioprocessing Summit) Aug 18-22. Boston, MA Rejuvenation Biotechnology: Emerging Regenerative Medicine Solutions for the Diseases of Aging conference Aug 21-23. Santa Clara, CA.

SEPTEMBER 2014 Terrapinn's Stem Cells USA and Regenerative Medicine Congress Sep 15-16. Boston, MA IBC's Cell Therapy Bioprocessing Sep 15-16. Arlington, VA TERMIS Asia Pacific Mtg Sep 24-17. Daegu, S. Korea

OCTOBER 2014 Cancer Immunotherapy 2014 Oct. 6. New York City, NY ARM's Stem Cell Meeting on the Mesa Oct 7-9. La Jolla, CA Fraunhofer Life Science Symposium"Medicinal Stem Cell Products Oct 9-10. Leipzig, Germany Translational Regenerative Medicine Congress Oct 21-22. Leipzig, Germany CCRM-SCN Till and McCulloch Meetings Oct 27-29. Ottawa, ON, Canada OMICS' International Conference and Exhibition on Cell and Gene Therapy Oct 27-29. Las Vegas, NV

NOVEMBER 2014 ISSCR/SSCS Global Controls in Stem Cells Nov 5-7, 2014. Singapore Society for Immunotherapy of Cancer Annual Meeting Nov 6-9. National Harbor, MD International Conference on Stem Cells and Cancer (ICSCC-2014): Proliferation, Differentiation and Apoptosis Nov 8-10. New Delhi, India IFATS Annual Mtg Nov 13-16. Amsterdam, NL BIT's World Congress of Regenerative Medicine & Stem Cells (RMSC2014) Nov 13-16.Haikou, China Commercial Translation of Regenerative Medicine Nov/Dec ??. London, UK DECEMBER 2014 Cell Therapy Manufacturing Dec 3-4. Brussels, Belgium World Stem Cell Summit Dec 3-5. San Antonio, TX TERMIS Americas Mtg Dec 13-16. Washington, DC If I've missed an event you'd like to see added, please email me at lbuckler [at] celltherapygroup [dot] com.

See more here:
Cell Therapy Blog: Cell Therapy Conferences 2014

Adult stem cells can change the healthcare landscape

A recent Colorado political advertisement highlighting a candidates stance on stem cell research shows the issue is still at the forefront of public consciousness. Part of what makes stem cell research such a hot button issue is the number of persistent myths that propagate many of the heated emotions surrounding the topic.

Much of the stem cell controversy comes from the fact many people only know of embryonic stem cells, which are generated from fertilized, frozen eggs at in-vitro fertilization centers. These are not the only type of stem cells. Other types include umbilical cord blood and adult stem cells.

Umbilical cord blood is extracted from birth and preserved for the future benefit of the child. While this type of stem cell technique is safe and it is becoming commonplace to store the cells, there is currently no way to utilize these cells beyond compassionate care cases which are few and far between. However, adult stem cells are currently in clinical use today and are easily and safely harvested from the patients fat and bone marrow reserves. The adult stem cells can be utilized for a variety of treatment options, which include joint, ligament and tendon injuries, back pain, and autoimmune diseases.

Polls indicate a shifting paradigm in how people view stem cell use and research. A Pew Research survey conducted in 2013 revealed only 16 percent believed non-embryonic stem cell research was immoral. Pope Emeritus Benedict XVI recently gave his approval on adult stem cell research, I pray that your commitment to adult stem cell research will bring great blessings for the future of man and genuine enrichment to his culture.

Those with an understanding of adult stem cells know there is no controversy as they do not require the harming of an embryo. While progress in the realm of public opinion is being made, regulatory and administrative difficulties are still hampering medical innovation according to some healthcare experts.

Adult stem cells hold great promise for the future of medicine because of their potential to improve cartilage health, repair lumbar discs, and slow progression of autoimmune diseases. The ability to utilize stem cells from ones own body to safely and naturally heal itself from many different ailments is beginning to revolutionize healthcare.

With more public support and cooperative regulatory policies, adult stem cells have the potential to forever change the healthcare landscape as profoundly as the mark antibiotics made on medicine.

Dr. Scott Brandt

ThriveMD Aspen

Read the original post:
Letter: Adult stem cells can change the healthcare landscape

Stem Cell Therapy | stem cell mobilization gcsf
http://www.arthritistreatmentcenter.com Another breakthrough in stem cell science and we have lab rats to thank for it next Osteoarthritis in rats responds to stem cell mobilization therapy...

By: Nathan Wei

Read the rest here:
Stem Cell Therapy | stem cell mobilization gcsf - Video

Adler Footcare - Stem Cell Therapy
Backed by years of research, thousands of happy patients, and faster healing time is the latest in ethical stem cell treatments for foot pain offered at Adle...

By: Adler Footcare

Go here to see the original:
Adler Footcare - Stem Cell Therapy - Video

The central nervous system in vertebrates develops from the neural tube, which is the basis for the differentiation in spinal cord and brain. Professor Elly Tanaka and her research group at the DFG Research Center for Regenerative Therapies Dresden -- Cluster of Excellence at the TU Dresden (CRTD) demonstrated for the first time the in vitro growth of a piece of spinal cord in three dimensions from mouse embryonic stem cells. Correct spatial organization of motor neurons, interneurons and dorsal interneurons along the dorsal/ventral axis was observed. This study has been published online by the American journal Stem Cell Reports.

For many years Elly Tanaka and her research group have been studying the regenerative potential of axolotls at the molecular level. The Mexican salamanders have the potential to regenerate their spinal cord and other organs to restore full functionality after injury. Mammals such as humans are not able to regenerate most organs. The restoration of the spinal cord in axolotl occurs in a three dimensional structure similar to an embryonic spinal cord. Due to their positions in the tissue, cells in the regenerated spinal cord know which function to perform in the restored tissue. "In this study we applied the knowledge gained about the regenerative potential in axolotls to a mammal, the mouse" explains Professor Elly Tanaka.

Single mouse embryonic stem cells embedded in a three-dimensional matrix and were grown in neural differentiation medium led to the clonal development of neuroepithelial cysts. These cysts settled in the midbrain and hindbrain along the neural axis. "Our goal, however, was to generate spinal cord in vitro," says Dr. Andrea Meinhardt, a postdoc at the CRTD. "For this reason we added retinoic acid to the culture medium on the second day of the 3D cell culture." The result not only caused the neural tissue to switch to spinal cord but also induced the formation of a local signaling center for forming all the different cell types of the spinal cord. "For the first time we could hereby reconstruct the structure of a typical embryonic neural tube in vitro," said Andrea Meinhardt.

"With this study we have moved a tiny step closer to turn the idea of constructing a three-dimensional piece of spinal cord for transplantation in humans into reality" says Elly Tanaka.

Story Source:

The above story is based on materials provided by Technische Universitaet Dresden. Note: Materials may be edited for content and length.

Continued here:
Reconstruction of patterned piece of spinal cord in 3D culture

Irelands first human stem cell trial using lab-grown cells is due to get underway in Galway in the new year following approval from the medicines watchdog.

The trial will involve extracting adult mesenchymal stem cells (MSC) from the bone marrow of patients with a condition known as critical limb ischemia (CLI) a severe blockage of the arteries resulting in marked reduction in blood flow to the extremities.

Reduction in blood flow to the legs puts patients at risk of gangrene, ulceration, and amputation, and the Galway trial will look at the use of MSCs to grow new stems cells which will then be injected back into the patients leg with the hope of growing new blood cells and improving circulation.

The harvested stem cells will be grown to much greater quantities in a highly specialised lab before being injected back into the patients leg.

Tim OBrien, director of the Galway-based Regenerative Medicine Institute, said their research was focused on whether MSC therapy could improve blood flow to the legs in patients with CLI a condition common in diabetics and therefore avoid the need for amputation. The trial is aimed predominantly at testing the safety and feasibility of what is very much an experimental therapy, Prof OBrien said.

We will be doing a dose escalation study, with some patients given a small dose, others a medium dose and the remainder a high dose, he said. We want to try and establish how many cells do you need to give a patient.

The study, the first in humans in Ireland, will be a year-long study involving nine patients. Prof OBrien said they would not be advertising for participants, but rather would let clinicians know and await referrals of suitable patients.

In the meantime, they would be preparing the custom-built facility where the cells are grown, at the Centre for Cell Manufacturing Ireland in NUI Galway, the first such facility in Ireland to receive a licence from the Health Products Regulatory Authority.

Prof OBrien said MSCs have a lot of properties that may make them useful in treating a wide variety of disease because of their reparative and regenerative qualities.

Prof OBrien delivered a talk yesterday on the Therapeutic Potential of MSCs in Diabetic Complications on the second day of a two-day international stem cell conference at NUI Galway.

Continued here:
Lab-grown stem cell trial gets green light

DALLAS, October 29, 2014 /PRNewswire/ --

According to the new market research report The"Cell Expansion Marketby Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative Medicine, Clinical Diagnostics), End User (Hospital, Biotechnology, Cell Bank) - Forecast to 2019", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Cell Expansion Market along with the estimates and forecasts of the revenue and share analysis.

Browse 149 Market Data Tables and 56 Figures spread through 224 Pages and in-depth TOC on"Cell Expansion Market"

http://www.marketsandmarkets.com/Market-Reports/cell-expansion-market-194978883.html

Early buyers will receive 10% customization on this report.

The global Cell Expansion Market is expected to reach $14.8 Billion by 2019 from $6.0 Billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019.

The report segments this market on the basis of product, cell type, application, and end user. Among various applications, the regenerative medicines is expected to account for the largest share in 2014 and is expected to account for the fastest-growing segment in the cell expansion market, owing to technological advancement due to which new products are being launched in the market. Furthermore, rising investments by companies and government for research is another major reason for the growth of this market.

Based on geography, the global Cell Expansion Market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2014. The large share of this region can be attributed to various factors including increasing government support for cancer and stem cell research and increasing prevalence of chronic diseases in this region.

Further Inquiry:http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=194978883

Prominent players in the Cell Expansion Market are Becton, Dickinson and Company (U.S.), Corning Incorporated (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K.), Merck Millipore (U.S.), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Sigma-Aldrich Corporation (U.S.), Terumo BCT (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Read more here:
Cell Expansion Market Worth $14.8 Billion by 2019